In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Leadership

Set Alert for Leadership

Trump’s Next 1,000 Days: Advice For The Pharma C-suite

Although signs suggest the Trump Administration is moving back to the establishment center, biopharma’s knowledge elites remain in the populists’ crosshairs. It’s vital to change the narrative on medicines and markets. In this brief opinion piece In Vivo provides seven ways for the C-suite to do just that.

BioPharmaceutical Leadership Business Strategies
Advertisement

Latest From Leadership

Podcast: Trump's 100 Day Test

Trump-watchers, check out our new podcast covering Trump's first months in office and the full GOP policy agenda. (Free with registration.)

BioPharmaceutical US Election 2016

Execs On The Move, April 2017

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

Personalized Medicine: A Patient Primer On Best Practice

Personalized medicine is focused on meeting patients’ needs, but it also has the potential to transform the delivery and financing of health care. In Vivo probes the path toward meeting both goals in an in-depth interview with Eleanor Perfetto, SVP for strategic initiatives at the National Health Council, the DC-based patient advocacy organization whose members include groups representing 133 million patients nationwide.

Personalized Medicine Leadership

Execs On The Move, March 2017

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Leadership BioPharmaceutical

The Frost Factor: An M&A Leader's Standout Strategy For Opko Health

With CEO leadership in the biopharma industry more short-cycled than ever, billionaire entrepreneur Phillip Frost ranks as a competitor for the long game – the last man standing in an endurance test spanning four decades of exposure to every iteration of a fast-changing business model. Frost’s strategy at Opko eschews the approach of most of his CEO peers to seek therapeutic dominance in a narrow band of core competencies.

Business Strategies Deals

Execs On The Move, February 2017

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Leadership BioPharmaceutical
See All
UsernamePublicRestriction

Register